Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

被引:199
|
作者
Otocka-Kmiecik, Aneta [1 ]
Mikhailidis, Dimitri P. [2 ]
Nicholls, Stephen J. [3 ]
Davidson, Michael [4 ]
Rysz, Jacek [5 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland
[2] UCL, Sch Med, Dept Clin Biochem, London, England
[3] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[5] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
关键词
Dyslipidemia; High density cholesterol; Inflammation; Lipids; Therapy; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CHOLESTERYL ESTER TRANSFER; TRANSFER PROTEIN-INHIBITION; ELEVATED OXIDATIVE STRESS; TYPE-2; DIABETIC-PATIENTS; ACUTE CORONARY SYNDROMES; HIGH-RISK; ANTIINFLAMMATORY PROPERTIES; ANTIOXIDANT PROPERTIES;
D O I
10.1016/j.plipres.2012.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High density lipoprotein (HDL) has many properties, which contribute to its atheroprotective role. However, some recent clinical trials have identified subjects with the progression of atherosclerosis despite normal levels of HDL cholesterol. This raises the question if all subfractions of HDL have the same properties. Moreover, recent investigations have shown that both acute and chronic inflammation may lead to structural and functional changes of HDL, which render the particles proinflammatory. Although therapeutic agents that increase HDL levels are now quite well established it is not clear whether they influence HDL quality. We review the current state of knowledge on the properties of HDL and factors/therapeutic agents which may restrain the transformation of normal HDL into dysfunctional HDL (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:314 / 324
页数:11
相关论文
共 50 条
  • [41] The Multifunctional Protein BAG3 A Novel Therapeutic Target in Cardiovascular Disease
    Myers, Valerie D.
    McClung, Joseph M.
    Wang, JuFang
    Tahrir, Farzaneh G.
    Gupta, Manish K.
    Gordon, Jennifer
    Kontos, Christopher H.
    Khalili, Kamel
    Cheung, Joseph Y.
    Feldman, Arthur M.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (01): : 122 - 131
  • [42] Lipoprotein(a) as a novel therapeutic target for preventing cardiovascular disease: A whiter shade of pale?
    Fiuza, Manuela
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (07) : 495 - 496
  • [43] AMPK - A NOVEL THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASES
    Heidrich, F.
    Schuenemann, J.
    Mokashi, S. A.
    Schmitto, J. D.
    DRUGS OF THE FUTURE, 2010, 35 (05) : 429 - 435
  • [44] Gut microbiome as a novel cardiovascular therapeutic target
    Singh, Vishal
    Yeoh, Beng San
    Vijay-Kumar, Matam
    CURRENT OPINION IN PHARMACOLOGY, 2016, 27 : 8 - 12
  • [45] The glycocalyx: a novel diagnostic and therapeutic target in sepsis
    Uchimido, Ryo
    Schmidt, Eric P.
    Shapiro, Nathan I.
    CRITICAL CARE, 2019, 23 (1):
  • [46] Periostin: Novel diagnostic and therapeutic target for cancer
    Kudo, Y.
    Siriwardena, B. S. M. S.
    Hatano, H.
    Ogawa, I.
    Takata, T.
    HISTOLOGY AND HISTOPATHOLOGY, 2007, 22 (10) : 1167 - 1174
  • [47] The glycocalyx: a novel diagnostic and therapeutic target in sepsis
    Ryo Uchimido
    Eric P. Schmidt
    Nathan I. Shapiro
    Critical Care, 23
  • [48] 'Dysfunctional' adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander?
    Antoniades, Charalambos
    CARDIOVASCULAR RESEARCH, 2017, 113 (09) : 997 - 998
  • [49] HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
    Anish Bhatt
    Anand Rohatgi
    Current Atherosclerosis Reports, 2016, 18
  • [50] Mechanisms of Disease: HDL metabolism as a target for novel therapies
    Daniel J Rader
    Nature Clinical Practice Cardiovascular Medicine, 2007, 4 : 102 - 109